Tech Session III: Nanomedicine and Nanoscale Delivery (Bioengineering)
Leveraging Cell-Penetrating Peptides and Liposomes to Enhance Nanobody Therapy in Breast Cancer
Wednesday, July 16, 2025
10:54 AM - 11:05 AM EDT
Location: 120 B/C
Introduction: Breast cancer remains the most common cancer in women [1], highlighting the need for more effective treatments. While biologics like Trastuzumab and ADCs such as Kadcyla are approved, monoclonal antibodies (mAbs) have limitations that reduce their efficacy [2]. Nanobodies, derived from camelid heavy-chain antibodies, offer better tumor penetration and stability but face rapid renal clearance [3,4]. Modifying nanobodies with cell-penetrating peptides (CPPs) and incorporating them into CPP-modified liposomes presents an innovative strategy to ameliorate the pharmacokinetics further.
Learning Objectives:
At the completion of this activity, participants will know
Understand the advantages of Nanobodies over traditional monoclonal antibodies in cancer treatment.
Examine the strategies for modifying Nanobodies to improve their pharmacokinetics profile with CPPs.
Evaluate the potential of Nanobody-based liposomal formulations to enhance therapeutic efficacy.
Maria Palacios, B.sc – Student, Pharmaceutical Technology and Biopharmacy, Heidelberg University; Sabrina Wohlfart, Dr. – Post-Doc, Nuclear Medicine, Heidelberg University Hospital; Lisa Blank, B.sc – Student, Pharmaceutical Technology and Biopharmacy, Heidelberg University; Clara Certa, B.sc – Student, Pharmaceutical Technology and Biopharmacy, Heidelberg University; Gert Fricker, Professor – Head of Department, Pharmaceutical Technology and Biopharmacy, Heidelberg University; Walter Mier, Professor – Group Leader, Nuclear Medicine, Heidelberg University Hospital; Philipp Uhl, Junior Professor – Group Leader, Pharmaceutical Technology and Biopharmacy, Heidelberg University
